W

hen the Trump administration released its blueprint for coping with high drug costs last month, one particular idea was widely derided — requiring drug makers to include list prices in consumer advertising.

That’s because drug pricing is highly confusing and few people actually pay list prices. Nonetheless, the White House seems to believe that such transparency could force companies to compete on price.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • C’mon Globe – a story headline is embedded in the business section and readers have to “pay” (subscribe) to STAT+ to get the content?? The word “deceptive” comes to mind.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy